RVL Pharmaceuticals plc (NASDAQ: RVLP) announced today that its U.S. FDA-approved acquired blepharoptosis (ptosis) drug UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of a "Best in Innovation" award in the 12th Annual Beauty Awards conducted by New Beauty, a Sandow Publication.
In a record-breaking year of product introductions, over 10,000 products were submitted and tested by the editorial team of New Beauty and an independent brain trust of medical and industry professionals. The top 365 were selected in a range of categories for illustrious awards.
"We are thrilled to be acknowledged by New Beauty with an Innovation Award for UPNEEQ," said Chief Operating Officer JD Schaub. "We have full confidence that UPNEEQ, which is unmatched and emerging in the aesthetic marketplace, has the potential to address the significant unmet need in acquired ptosis therapy. Industry support and validation like this award from New Beauty is further proof of concept."
UPNEEQ, which is composed of oxymetazoline hydrochloride ophthalmic solution at 0.1%, received its final FDA approval in July 2020, introducing to the market the only non-surgical therapeutic approved for the condition.
Wednesday morning’s news release said UPNEEQ is a safe and effective, first-in-class treatment for acquired ptosis providing patients, eye care and all aesthetic providers a simple, convenient daily drop as of the national rollout in January 2022.
RVL shares nicked up two cents, or 1.2%, to $1.71.
